Maria Marco

Global Health R&D
Tres Cantos, MD 28760, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Structure-activity relationships of 1,5-dihydro-2H-benzo[b][1,4]diazepine-2,4(3H)-diones as inhibitors of Trypanosoma cruzi.

Structure-activity relationships of 1,5-dihydro-2H-benzo[b][1,4]diazepine-2,4(3H)-diones as inhibitors of Trypanosoma cruzi.

Journal: RSC medicinal chemistry

Published: February 28, 2025

DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1.

DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1.

Journal: Science translational medicine

Published: December 13, 2023

Short-course combination treatment for experimental chronic Chagas disease.

Short-course combination treatment for experimental chronic Chagas disease.

Journal: Science translational medicine

Published: December 13, 2023

Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors.

Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 28, 2023

Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.

Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.

Journal: European journal of medicinal chemistry

Published: February 15, 2022

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.

Journal: Journal of medicinal chemistry

Published: April 27, 2021

Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity.

Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity.

Journal: Journal of medicinal chemistry

Published: July 15, 2020

The Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani.

The Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani.

Journal: ACS infectious diseases

Published: January 23, 2020

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series.

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series.

Journal: Journal of medicinal chemistry

Published: October 29, 2019

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 10, 2019

Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals.

Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals.

Journal: Antimicrobial agents and chemotherapy

Published: February 05, 2018

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.

Journal: Journal of medicinal chemistry

Published: August 29, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026